Introduction: Hemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal immunoglobulin for intravenous administration [i.e., intravenous immunoglobulin (IVIG)].
plasma are present in polyvalent immunoglobulin G (IgG) products and are considered a probable risk factor for hemolysis. We hypothesized that, by excluding plasma from donors with high isoagglutinin titers, the final IVIG product would have a meaningful reduction in anti-A/B isoagglutinin titers.
Methods: A method for screening donor plasma for anti-A isoagglutinins using an Results: Screening of plasma from 705 donors identified 48 (6.8%) donors with high anti-A isoagglutinin titers in plasma (IAT agglutination score C2? in a 1:200 predilution). Exclusion of plasma from these donors resulted in a one-titer-step reduction of anti-A isoagglutinin in pooled plasma, confirmed by a twofold anti-A isoagglutinin concentration reduction measured by FACS anti-A (1,352 vs. 2,467 lg/g IgG). When the same screening and exclusion were applied to industrial-scale plasma pools (resulting in the exclusion of plasma from 5% of donors), anti-A isoagglutinins were reduced by one titer step in the final IVIG product. Anti-B isoagglutinins were also reduced by one titer step, as many donors with high anti-A isoagglutinins also have high anti-B.
Electronic supplementary material The online version of this article (doi:10.1007/s13554-014-0016-2) contains supplementary material, which is available to authorized users. [4] , which suggests greater relevance of anti-A isoagglutinin. Isoagglutinin concentrations are lower in some IVIG products prepared by ethanol fractionation, as that process leads to significant reduction of isoagglutinins [6] . Modern Ig purification processes are designed to keep the full antibody repertoire of the donated plasma and thus do not reduce isoagglutinins. An increase in the frequency of reported hemolytic events with IVIG in recent years [4] may be in part due to the introduction of these modern Ig purification processes, leading to higher isoagglutinin titers, in addition to the generally increased use of IVIG products.
Screening and exclusion of donors with high
anti-A/B isoagglutinin titers proved to be effective in preventing hemolytic reaction after ABO-incompatible platelet transfusion [7] . Screening for either anti-A or anti-B isoagglutinin alone may be sufficient to identify candidate donors for exclusion, as high titers of anti-A/B isoagglutinins tend to correlate in individual donors [8, 9] . To develop a screening program that can be used on an industrial scale, it is necessary to define a cut-off anti-A/B isoagglutinin level that produces isoagglutinin titer reduction in the final IVIG product with exclusion of a relatively small proportion of donors.
Versions of the indirect agglutination tests (IAT) and direct agglutination tests (DAT) [10] have been used to detect anti-A/B isoagglutinins in donor plasma [5, 7, 9] 
METHODS
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Method Development: Anti-A Isoagglutinin Donor Screening
Donors were randomly selected for screening from regular plasmapheresis donors at CSL Plasma centers in the US. Plasma donors gave written consent that their plasma may be used for research purposes.
Indirect Isoagglutinin Test in Gel Cards
Anti-A isoagglutinin titer in plasma of individual donors was measured by IAT in gel cards (IAT-GC) containing microcolumns filled with dextran acrylamide gel and rabbit anti- Donor plasma minipools were prepared by mixing 20 lL of plasma from each donor included in the development study (thus mimicking plasma pool preparation during Privigen production), with exclusion of donor plasma with agglutination scores C1?, C2?, or C3?. Anti-A isoagglutinin titer in minipools was measured by IAT-GC and an optimized IAT method in microtiter plates (IAT-PhEur/MTP) [10] . Double serial dilutions were used for titration; therefore, one titer step corresponded to a twofold change in isoagglutinin titer. Nonanti-A-screened plasma (a minipool prepared from plasma of all tested donors) was used for comparison in all tests. The anti-A-screened and non-anti-Ascreened lots of both plasma pools and final IVIG product were prepared with or without implementation of the anti-A donor screening, respectively. The anti-A-screened plasma pool lots used for anti-A/B isoagglutinin testing were drawn randomly and do not necessarily match the plasma pool lots (also anti-A-screened) that were used for production of the anti-A-screened final IVIG product. Laboratories-DiaMed GmbH), followed by centrifugation. The agglutination strength in each dilution was scored according to the RBC localization patterns as described above. The highest dilution with agglutination score C1?
Anti-A/B Isoagglutinin Detection in Plasma
was considered the endpoint titer.
Anti-A/B Isoagglutinin Detection in the Final IVIG Product
The concentration of anti-A/B isoagglutinins in the final IVIG product was measured according to PhEur 2.6.20, methods A and B 
RESULTS
Method Development: Anti-A Isoagglutinin Donor Screening
A total of 705 plasma samples collected from randomly selected individual donors were tested for anti-A isoagglutinin titers using IAT-GC. All reported agglutination scores for single-donor plasma are based on a 1:200 predilution. A small proportion of donors (n = 48; 6.8%; Table 1 , excluded donors) were identified as having high anti-A isoagglutinin levels [agglutination score 2? (5.4%) or 3?
(1.4%); Fig. 2 ]. The rest of the donors were either negative or weakly positive for anti-A isoagglutinin [agglutination score 0 (81%) or 1? (12.2%)]. No donors with agglutination score 4? were identified (Fig. 2) .
Plasma-donor minipools were prepared based on results of the anti-A donor screening.
Exclusion of donor plasma with agglutination score 3? did not result in a measurable anti-A reduction (as determined by IAT-GC; Fig. 3 
Anti-A/B Isoagglutinin Concentration in Plasma Pools
Both the highest and most frequent anti-A isoagglutinin titer observed in 120 anti-Ascreened plasma pool lots was 1 titration step lower than in 72 non-anti-A-screened lots (1:32 vs. 1:64; Fig. 4 ). The highest anti-B isoagglutinin titer observed in the same set of anti-A-screened plasma pool lots was one titration step lower than in the non-anti-A-screened lots (1:16 vs. 1:32; Fig. 4 ).
Anti-A/B Isoagglutinin Concentration in the Final IVIG Product
In 30 anti-A-screened Privigen lots analyzed by IAT-PhEur/MTP, both the highest (1:16 in 10% of lots) and the most frequent (1:8 in 90% of lots) anti-A isoagglutinin titers were reduced by 1 titer step compared with 651 historical, nonanti-A-screened lots (Fig. 5) . Similarly, a twostep reduction of the highest anti-B isoagglutinin titer was observed in the anti-Ascreened set (1:8 in 16.7% of lots) versus nonanti-A-screened set (1:32 in 0.2% of lots). The 
DISCUSSION
We have developed an anti-A donor screening assay based on measurement of anti-A A similar one-titer-step reduction was observed for anti-B isoagglutinin titers, consistent with the known correlation of high anti-A and anti-B
isoagglutinin titers in O blood group donors [8, 9] . These results strongly suggest that testing donors for anti-A isoagglutinin alone is sufficient for reduction of both anti-A and anti-B isoagglutinin in final IVIG products.
We presumed that a single test would be sufficient for each donor, rather than testing each donation, as isoagglutinin titers are not expected to change much over time [15] . All subsequent plasma donations from a donor with isoagglutinin titers above the cut-off would then be excluded from the production of IVIG, but not necessarily from the production of other plasma products, such as albumin or coagulation factors. The anti-A donor screening assay proved to be compatible with the Privigen production process on an industrial scale, suggesting that donor screening can be routinely applied to IVIG production.
Comparison of the anti-A-screened and nonanti-A-screened plasma pool and final IVIG product lots was purely descriptive due to the very different numbers of lots, time of plasma collection and homogeneity of the donor groups. Nonetheless, we consider this comparison to be valid, as the same standardized plasma collection and storage conditions, as well as isoagglutinin detection methods, were used for all samples. We concluded that by donor screening and exclusion of plasma from donors with high anti-A isoagglutinin titers, both anti-A and anti-B isoagglutinins can be reduced by one titer step (i.e., the concentration can be reduced by 50%). Privigen 
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